Tag: MONOGRAPH

  • Cinnarizine

    Diphenylmethyl-piperazine calcium channel blocker / antihistamine

    A diphenylmethyl-piperazine T-type calcium channel blocker with antihistamine activity; used for vertigo, motion sickness, and cerebrovascular disease.

    Abstract

    Cinnarizine (1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine; CAS 298-57-7; molecular formula C26H28N2; molecular weight 368.52) is a diphenylmethyl-piperazine multi-target compound developed at Janssen and approved in many European and Asian markets in the 1970s. Mechanism: T-type voltage-gated calcium channel inhibition (cerebrovascular dilation, vestibular nerve effects), H1 antihistamine activity, and weak D2 dopamine receptor antagonism. The combined activity supports use in vestibular disorders, motion sickness, and cerebrovascular insufficiency. The D2 antagonism produces a small but real risk of extrapyramidal side effects (parkinsonism, tardive dyskinesia) with long-term use, particularly in elderly patients; this has limited use in some jurisdictions. Plasma half-life is approximately 4 hours. Approved for vertigo, motion sickness, and cerebrovascular disease in EU and Asia; not approved in the US. Used as a multi-target reference compound for vestibular pharmacology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • URB597

    Selective FAAH inhibitor (research)

    A carbamate inhibitor of fatty acid amide hydrolase (FAAH); the canonical research probe for elevating endogenous anandamide.

    Abstract

    URB597 (KDS-4103, cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester; CAS 546141-08-6; molecular formula C20H22N2O3; molecular weight 338.40) is a covalent carbamate inhibitor of fatty acid amide hydrolase (FAAH) developed by Piomelli and colleagues at UC Irvine. The compound carbamoylates the active-site serine of FAAH, producing irreversible enzyme inactivation. Selective for FAAH over MAGL and other lipases. Pharmacological consequence: elevation of endogenous anandamide and other N-acylethanolamides without direct CB receptor agonism. The behavioral profile differs from direct CB1 agonists like THC: anxiolytic and analgesic effects without the catalepsy, hypothermia, and intoxication characteristic of CB1 full agonism. Phase 2 clinical trials in major depressive disorder did not demonstrate efficacy; the compound did not advance to phase 3. Used as the canonical FAAH inhibitor in academic neuroscience.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cyproheptadine

    First-generation antihistamine + 5-HT2 antagonist

    A piperidine first-generation antihistamine with 5-HT2A and 5-HT2C antagonist activity; used for appetite stimulation, serotonin syndrome reversal, and migraine prophylaxis.

    Abstract

    Cyproheptadine (4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; CAS 129-03-3; molecular formula C21H21N; molecular weight 287.40) is a piperidine first-generation antihistamine with potent 5-HT2A and 5-HT2C antagonist activity, approved by the FDA in 1961 (Periactin). The compound combines H1 antihistamine activity (Ki approximately 1 nM, comparable to diphenhydramine) with strong 5-HT2 antagonism (Ki approximately 1 nM at 5-HT2A); the combined activity drives appetite stimulation (5-HT2C antagonism, the same mechanism as the appetite gain seen with olanzapine and clozapine), serotonin syndrome reversal, and migraine prophylaxis. Plasma half-life is approximately 8 hours. Approved for allergic conditions; off-label use in failure-to-thrive (pediatric appetite stimulation), serotonin syndrome (the only specific antidote besides supportive care), and post-SSRI sexual dysfunction (5-HT2A antagonism). Used as the canonical 5-HT2 antagonist antihistamine in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • D-Serine

    Endogenous NMDA receptor co-agonist

    D-stereoisomer of serine; an endogenous obligatory co-agonist at the NMDA receptor glycine site.

    Abstract

    D-serine ((R)-2-amino-3-hydroxypropanoic acid; CAS 312-84-5; molecular formula C3H7NO3; molecular weight 105.09) is the D-stereoisomer of serine, an endogenous obligatory co-agonist at the glycine site of NMDA receptors. The compound is biosynthesized in the brain by serine racemase (the enzyme that converts L-serine to D-serine) and is metabolized by D-amino acid oxidase (DAAO). D-serine is the principal endogenous co-agonist for synaptic NMDA receptors in the cortex and hippocampus, while glycine itself co-agonizes extrasynaptic NMDA receptors. Pharmacologically, exogenous D-serine elevates NMDA receptor function, with research interest in schizophrenia (where reduced NMDA function is hypothesized as a contributor to negative symptoms and cognitive deficits) and depression (NMDA modulation as antidepressant target). Phase 2 trials in schizophrenia have shown small effects. Plasma half-life is approximately 4 hours; oral bioavailability is moderate. The DAAO inhibitor approach is an alternative to direct D-serine administration. Used as the canonical NMDA glycine-site co-agonist in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • SRT1720

    Selective SIRT1 activator

    An imidazothiazole SIRT1 activator; the structural lineage compound from which SRT2104 was developed.

    Abstract

    SRT1720 (CAS 925434-55-5; molecular formula C22H19N5OS2; molecular weight 433.55) is an imidazothiazole SIRT1 activator developed at Sirtris Pharmaceuticals as a potent (approximately 1000-fold over resveratrol) and selective sirtuin 1 activator. Mechanism is allosteric SIRT1 activation comparable to SRT2104. Mouse studies demonstrated lifespan extension in diet-induced obese mice, improved metabolic parameters, and reduced age-related pathology. The compound was the foundation for the broader Sirtris drug discovery program; SRT2104 was developed as a more drug-like successor with better human pharmacokinetics. SRT1720 is used preferentially in academic research where the established mouse pharmacology is valuable. Plasma half-life is approximately 8 to 10 hours.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • TB-500

    Synthetic peptide fragment of thymosin beta-4

    A 43-residue acetylated synthetic peptide derived from the actin-sequestering protein thymosin beta-4, studied for tissue repair, cell migration, and angiogenic endpoints.

    Abstract

    TB-500 is the common research-grade designation for a synthetic acetylated peptide whose primary sequence is a fragment of human thymosin beta-4 (Tbeta4), a 43-residue actin-binding protein expressed at high concentration in platelets, leukocytes, and many other cells. The most frequently cited research-grade preparation is the full-length Tbeta4 sequence (43 amino acids; molecular weight approximately 4963 Da; CAS 77591-33-4) acetylated at the N-terminus to mimic the native post-translational modification. A small minority of vendor literature has used “TB-500” to refer to a shorter active fragment (LKKTETQ, residues 17 through 23 of Tbeta4), which is a different molecule with a different mass; investigators should confirm by mass spectrometry which sequence has been supplied. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Ipamorelin

    Pentapeptide growth hormone secretagogue, ghrelin receptor agonist

    A 5-residue selective growth hormone secretagogue developed at Novo Nordisk in the late 1990s, characterized by GH release without coincident ACTH or prolactin stimulation.

    Abstract

    Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2; CAS 170851-70-4; molecular formula C38H49N9O5; molecular weight 711.86) is a synthetic pentapeptide growth hormone secretagogue (GHS) developed at Novo Nordisk in the mid-1990s and disclosed in a 1998 paper by Raun and colleagues. Ipamorelin is a selective agonist of the growth hormone secretagogue receptor 1a (GHS-R1a, the ghrelin receptor), the receptor through which the endogenous peptide ghrelin and the small-molecule MK-0677 also act. Selective activation of GHS-R1a triggers pulsatile growth hormone (GH) release from the anterior pituitary without the concurrent stimulation of cortisol, ACTH, or prolactin that complicates the pharmacology of older GHS compounds (GHRP-2, GHRP-6, hexarelin). The selectivity profile is the basis on which Ipamorelin remains the most-cited research-grade GHS in the post-2010 literature. The compound was advanced through Phase 2 trials by Helsinn Therapeutics for postoperative ileus before development was discontinued for commercial reasons. Reported preclinical activities include dose-dependent GH pulse induction, increased IGF-1 axis activity over multi-day administration, modest effects on appetite (smaller than ghrelin’s), and accelerated bone mineral density gains in osteopenic rodent models. The compound is not approved by any regulatory authority for human or veterinary use. The literature base is solid for the basic pharmacology but limited for long-term safety data in humans; the clinical record is principally from a single short-term ileus indication.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • CJC-1295 (No DAC)

    Synthetic 29-residue analog of growth hormone-releasing hormone

    A 29-amino-acid GHRH analog with four point substitutions that confer enzymatic stability against dipeptidyl peptidase 4, the principal degradation pathway for native GHRH.

    Abstract

    CJC-1295 (No DAC), often abbreviated CJC-1295 nDAC and known in the literature as modified GRF(1-29) or simply Mod-GRF, is a synthetic 29-residue analog of human growth hormone-releasing hormone (GHRH) bearing four point mutations relative to the native sequence (CAS 446036-97-1; molecular weight 3367.94). The substitutions are tyrosine-1 to D-alanine (DPP-4 resistance), alanine-8 to glutamine (improved chemical stability), arginine-15 to glutamine (DPP-4 resistance and stability), and asparagine-27 to leucine (improved hydrophobicity and resistance to deamidation). The result is a GHRH analog with substantially extended biological half-life relative to native GHRH (which has a serum half-life under 10 minutes due to rapid DPP-4 cleavage at the N-terminal tyrosine). CJC-1295 nDAC retains the receptor specificity of native GHRH and stimulates pituitary somatotrophs through the GHRH receptor, producing a pulsatile GH release pattern. The “DAC” suffix in the related compound CJC-1295 with DAC refers to a drug affinity complex (a maleimidopropionic acid linker that covalently attaches to serum albumin) that further extends the half-life from approximately 30 minutes to multiple days; the No DAC version omits the linker and the prolonged albumin binding. The two compounds have different pharmacokinetic profiles and different appropriate use cases. CJC-1295 nDAC was originally developed at ConjuChem, Inc., as the parent platform for the DAC-modified version that progressed to Phase 2 trials. The compound is not approved by any regulatory authority for human or veterinary use.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • KPV

    Tripeptide C-terminal fragment of alpha-melanocyte stimulating hormone

    A 3-amino-acid tripeptide derived from the C-terminus of alpha-MSH, characterized for anti-inflammatory effects in colitis, dermatitis, and hepatic injury models.

    Abstract

    KPV (sequence Lys-Pro-Val-OH; CAS 67727-97-3; molecular formula C16H30N4O4; molecular weight 342.43) is a synthetic tripeptide corresponding to residues 11-13 of alpha-melanocyte stimulating hormone (alpha-MSH), the C-terminal fragment that retains anti-inflammatory activity in many of the published preclinical models of acute and chronic inflammation. The tripeptide was originally characterized by Catania and Lipton in the early 1990s as part of a structure-activity relationship study of the alpha-MSH inflammatory pharmacology, with the goal of identifying a small fragment that retained the parent hormone’s anti-inflammatory effects without the pigmentation, body temperature, and feeding-behavior effects mediated by the N-terminal portion of the hormone. KPV reproduced the anti-inflammatory effects of alpha-MSH in rodent models of acute lung injury, dextran sulfate sodium-induced colitis, contact dermatitis, and hepatic ischemia-reperfusion injury. The mechanism involves attenuation of NF-kappa-B activation, reduced pro-inflammatory cytokine production by activated immune cells, and modulation of the melanocortin system through receptors that are not yet fully characterized for the tripeptide fragment. There is no FDA-approved IND for KPV in any indication; preliminary clinical work has explored topical KPV preparations for ulcerative colitis and inflammatory dermatologic conditions. The compound is widely used in research-grade work on inflammation and tissue injury. The principal limitations on the strength of the evidence are the relatively small published literature compared to BPC-157 or TB-500 and the limited human pharmacokinetic data.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • MOTS-c

    16-residue mitochondrial-derived peptide, AMPK pathway modulator

    A short open reading frame encoded within mitochondrial 12S rRNA, reported to modulate insulin sensitivity, exercise capacity, and metabolic homeostasis through AMPK-dependent mechanisms.

    Abstract

    MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA-c; sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg; CAS 1627580-64-6; molecular formula C100H152N28O22S2; molecular weight 2174.59) is a 16-amino-acid peptide encoded within an open reading frame in the mitochondrial 12S ribosomal RNA gene MT-RNR1, first characterized in 2015 by Changhan Lee, Pinchas Cohen, and colleagues at the University of Southern California. It is the first short open reading frame (sORF) peptide identified in the mitochondrial genome, and its discovery has opened a substantial line of work on small mitochondrial-encoded peptides as endocrine and paracrine signals. Reported activities include enhanced insulin sensitivity in diet-induced and genetic obesity models, increased exercise capacity, improved glucose homeostasis through AMP-activated protein kinase (AMPK) activation, attenuated age-related insulin resistance, and effects on bone mineral density and immune function. Plasma MOTS-c levels decline with age in humans, which is the rationale for the geroprotective framing of the compound in research-grade vendor literature. The published preclinical literature is robust and has expanded steadily since 2015 with multiple independent laboratories contributing replication and extension studies. There is no FDA-approved IND for MOTS-c in any indication; preliminary Phase 1 work has been initiated by CohBar, Inc., the company that has licensed the platform from USC. The compound is not approved by any regulatory authority for human or veterinary use.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.